Page last updated: 2024-11-04

sulfasalazine and Congenital Zika Syndrome

sulfasalazine has been researched along with Congenital Zika Syndrome in 1 studies

Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Abrams, RPM1
Yasgar, A1
Teramoto, T1
Lee, MH1
Dorjsuren, D1
Eastman, RT1
Malik, N1
Zakharov, AV1
Li, W1
Bachani, M1
Brimacombe, K1
Steiner, JP1
Hall, MD1
Balasubramanian, A1
Jadhav, A1
Padmanabhan, R1
Simeonov, A1
Nath, A1

Other Studies

1 other study available for sulfasalazine and Congenital Zika Syndrome

ArticleYear
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
    Proceedings of the National Academy of Sciences of the United States of America, 2020, 12-08, Volume: 117, Issue:49

    Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr

2020